Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIA clinical trial assessing AL001 for treatment of Major Depressive Disorder

Next Previous
Trial Profile

Phase IIA clinical trial assessing AL001 for treatment of Major Depressive Disorder

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lithium cocrystal Alzamend Neuro (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Alzamend Neuro

Most Recent Events

  • 07 May 2025 According to an Alzamend Neuro media release, the company announced its partnership with Mint Labs Inc. d/b/a QMENTA a leading medical imaging artificial intelligence company, to support its five upcoming Phase II clinical trials of AL001 at Massachusetts General Hospital.
  • 18 Mar 2025 According to Alzamend Neuro media release,company plans to initiate highly anticipated phase II clinical study of AL001 for treatment of patients with MDD in the fourth quarter of 2025.
  • 12 Aug 2024 According to Alzamend Neuro media release, the company announced Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, involving Patients with Major Depressive Disorder. Dr. Ovidiu Andronesi is a principal investigator on the study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top